Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) just unveiled an update.
Nanjing Leads Biolabs Co., Ltd. has announced the closure of its H shares register from December 12 to December 17, 2025, in preparation for an extraordinary general meeting (EGM) scheduled for December 17, 2025. This meeting is significant for shareholders as it will determine their eligibility to attend and vote, potentially impacting the company’s governance and future strategic decisions.
The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.
More about Nanjing Leads Biolabs Co., Ltd. Class H
Nanjing Leads Biolabs Co., Ltd. is a joint stock company established in the People’s Republic of China, operating within the biotechnology industry. The company is listed on the Hong Kong Stock Exchange and focuses on the development and commercialization of biotechnological products.
Average Trading Volume: 733,115
Current Market Cap: HK$10.27B
Learn more about 9887 stock on TipRanks’ Stock Analysis page.